Novan — Corporate Update (August 2017)
25 slides from Novan's corporate update, Aug 2, 2017
Slide 1: Novan Webcast August 2, 2017
Novan Webcast August 2, 2017 Exhibit 99.1
Slide 2: Agenda
Agenda Purpose of Webcast Introductions Scientific Foundation Clinical Overview Financial Update Summary Q&A 1 2 3 4 5 6 7 Page 1
Slide 3: Agenda
Agenda Purpose of Webcast Introductions Scientific Foundation Clinical Overview Financial Update Summary Q&A 1 2 3 4 5 6 7 Page 2
Slide 4: Purpose of Webcast
Purpose of Webcast Provide an overall company update – as of August 2, 2017 Areas to be covered: A reminder regarding the underlying science as core to the company A “point in time” picture of the clinical pipeline and portfolio Share anticipated portfolio advancements for 2H 2017 and 1H 2018 for cu
Slide 5: Agenda
Agenda Purpose of Webcast Introductions Scientific Foundation Clinical Overview Financial Update Summary Q&A 1 2 3 4 5 6 7 Page 4
Slide 6: Introductions
Introductions Participants on webcast Robert Ingram – Executive Chairman Nate Stasko – Co-Founder, Chief Scientific Officer and President Paula Brown Stafford – Chief Development Officer Kelly Martin – Interim Chief Executive Officer Others available to participate in the investor Q&A Stan Hollenbac
Slide 7: Agenda
Agenda Purpose of Webcast Introductions Scientific Foundation Clinical Overview Financial Update Summary Q&A 1 2 3 4 5 6 7 Page 6
Slide 8: Scientific Foundation: Nitric Oxide Mechanism of Action
Scientific Foundation: Nitric Oxide Mechanism of Action Science – Breakthrough of the Year (1992) Nobel Prize in Medicine (1998) >100,000 peer reviewed manuscripts Broad Spectrum Antimicrobial Anti-bacterial Antiviral Antifungal Immunomodulatory Agent Decreases key biomarkers for inflammation Inhibi
Slide 9: Scientific Foundation: Nitric Oxide Platform
Scientific Foundation: Nitric Oxide Platform Page 8 NVN1000 Nitric Oxide Proprietary chemistry that stores large amounts of nitric oxide in solid form Macromolecular NCEs Drug Candidates Indication specific formulations with differentiated nitric oxide release rates Formulation Science Nitricil Tech
Slide 10: Scientific Foundation: Therapeutic Applications
Scientific Foundation: Therapeutic Applications Androgenetic alopecia Bromhidrosis Hyperseborrhea Medical Aesthetics Contact dermatitis Psoriasis Atopic dermatitis Inflammatory Skin Diseases Warts (HPV) Cold sores (HSV) Molluscum (Pox) Viral Skin Infections Multi-factorial Diseases Acne vulgaris Seb
Slide 11: Agenda
Agenda Purpose of Webcast Introductions Scientific Foundation Clinical Overview Financial Update Summary Q&A 1 2 3 4 5 6 7 Page 10
Slide 12: Clinical Overview: Pipeline - as of August 2, 2017
Clinical Overview: Pipeline - as of August 2, 2017 Multi-factorial* Anti-inflammatory Antiviral Product Candidates Indication Preclinical Phase 1 Phase 2 Phase 3 SB204 Acne Vulgaris SB206 Genital Warts SB414 Psoriasis Atopic Dermatitis SB208 Tinea pedis / Onychomycosis Antifungal Page 11 * Includes
Slide 13: Clinical Overview: Potential Pipeline Progression – H1 2018
Clinical Overview: Potential Pipeline Progression – H1 2018 Multi-factorial* Anti-inflammatory Antiviral Product Candidates Indication Preclinical Phase 1 Phase 2 Phase 3 SB204 Acne Vulgaris SB206 Genital Warts Molluscum SB414 Psoriasis Atopic Dermatitis SB208 Tinea pedis / Onychomycosis Antifungal
Slide 14: Clinical Overview: Proposed Activity & Events
Clinical Overview: Proposed Activity & Events SB206 EGW SB206 Molluscum SB414 Atopic Dermatitis SB208 Onychomycosis 2H 2017 1H 2018 Not a current focus SB204 Acne Vulgaris SB414 Psoriasis Initiate Phase 3 Initiate Phase 2 Conduct PK trials Complete long-term safety study Complete dermal safety studi
Slide 15: Clinical Overview: SB204, Acne Vulgaris Program
Clinical Overview: SB204, Acne Vulgaris Program Completed Long Term Safety Study: no significant adverse events observed Continue to do work on behalf of Sato – our Japanese partner on SB204 FDA granted meeting to be held in 3Q 2017 Goal of FDA meeting: seek programmatic clarity regarding possible c
Slide 16: Clinical Overview: SB206, EGW Program
Clinical Overview: SB206, EGW Program Page 15 Market Overview Next Steps >500,000 cases of genital warts in the US Currently no FDA approved treatments with an antiviral mechanism for the treatment of warts Topical and ablative procedures for genital warts remain ineffective in achieving long term w
Slide 17: Clinical Overview: Molluscum Program
Clinical Overview: Molluscum Program Page 16 Next Steps Clinical Background Molluscum is a contagious skin infection caused by the molluscipoxvirus Affects ~6M Americans, mostly children Greatest incidence in children aged 1 to 12 years Average time to resolution is 13 months1 30% of children have l
Slide 18: Clinical Overview: SB414, Psoriasis and Atopic Dermatitis
Clinical Overview: SB414, Psoriasis and Atopic Dermatitis Page 17 Market Overview Next Steps Clinical Background Nitric oxide has the potential to disrupt the propagation of IL-17 locally in the skin through its ability to disrupt the assembly and activity of the NLRP3 inflammasome¹ SB414 displayed
Slide 19: Clinical Overview: Proposed Activity & Events
Clinical Overview: Proposed Activity & Events SB206 EGW SB206 Molluscum SB414 Atopic Dermatitis SB208 Onychomycosis 2H 2017 1H 2018 Not a current focus SB204 Acne Vulgaris SB414 Psoriasis Initiate Phase 3 Initiate Phase 2 Conduct PK trials Complete long-term safety study Complete dermal safety studi
Slide 20: Agenda
Agenda Purpose of Webcast Introductions Scientific Foundation Clinical Overview Financial Update Summary Q&A 1 2 3 4 5 6 7 Page 19
Slide 21: Financial Update
Financial Update Page 20 We expect to file our 10Q for the quarterly period ended June 30, 2017 on August 11, 2017 Cash at June 30, 2017 of over $19 million Steps have been taken to focus activity and resources, align talent and capability, and extend the operating and financial runway Strengthening
Slide 22: Agenda
Agenda Purpose of Webcast Introductions Scientific Foundation Clinical Overview Financial Update Summary Q&A 1 2 3 4 5 6 7 Page 21
Slide 23: Summary
Summary Focus for the company: high quality execution and moving the science/clinical assets forward Near term goal to enable increase in operating “runway” Primary clinical focus over the next 24 months: antiviral clinical work in EGW and Molluscum Secondary clinical and nitric oxide mechanistic fo
Slide 24: Q & A
Q & A Page 23
Slide 25: Forward-looking statements
This presentation includes forward-looking statements that reflect our current views with respect to, among other things, our operations and financial performance. These forward-looking statements are included throughout this presentation. We have used the words “anticipate,” “assume,” “believe,” “c